Nitroglycerin provocation in normal subjects is not a useful human migraine model?
|
|
- Griselda Hensley
- 5 years ago
- Views:
Transcription
1 Original Article Nitroglycerin provocation in normal subjects is not a useful human migraine model? Cephalalgia 30(8) ! International Headache Society 2010 Reprints and permissions: sagepub.co.uk/journalspermissions.nav DOI: /j x cep.sagepub.com JF Tvedskov, HK Iversen, J Olesen and P Tfelt-Hansen Abstract Provoking delayed migraine with nitroglycerin in migraine sufferers is a cumbersome model. Patients are difficult to recruit, migraine comes on late and variably and only 50 80% of patients develop an attack. A model using normal volunteers would be much more useful, but it should be validated by testing the response to drugs of known efficacy in acute migraine. Furthermore, treatment during headache rather than pretreatment is the most naturalist method. To fulfil these requirements we used continuous long-lasting infusion of glyceryl trinitrate (GTN) 0.25 mgkg 1 min 1 for 140 min and gave aspirin 1000 mg, zolmitriptan 5 mg or placebo to normal healthy volunteers. The design was double-blind, placebo-controlled three-way crossover. Our hypothesis was that these drugs would be effective in the treatment of the mild constant headache induced by long-lasting GTN infusion. The headaches did not fulfil the International Headache Society diagnostic criteria for migraine without aura. Moreover, there was no effect on headache of either zolmitriptan or aspirin. Thus our hypothesis was disproved and we conclude that our model is not valid for the testing of new acute antimigraine drugs. Our experiment suggests that headache caused by direct nitric oxide (NO) action in the continued presence of NO is very resistance to analgesics and to specific acute migraine treatments. This suggests that NO works very deep in the cascade of events associated with vascular headache, whereas tested drugs work higher in the cascade. The model suggested here should therefore be tested with other headache/ migraine-provoking agents that supposedly work higher in the cascade of events. The need for human models persists, but the solution to this problem is still pending. Keywords Glyceryl trinitrate, aspirin, zolmitriptan, human headache model Date received: 27 August 2008; accepted: 21 June 2009 Introduction Human models of migraine have recently received increasing interest. Studies with nitroglycerin, glyceryl trinitrate (GTN), calcitonin gene-related peptide (CGRP) and other molecules have elucidated aspects of migraine mechanisms. Although these substances cause headache that has some migrainous features during infusion and shortly after in normal volunteers, as well as in migraine patients, only migraine patients develop a delayed headache fulfilling diagnostic criteria for a migraine attack (1). Given the limited predictability of existing animal models of migraine, it is tempting to suggest that human models as described could be useful in the testing of new antimigraine compounds. The most reliable and strongest provoking agent is GTN. This model can be applied in many different ways with a different dose, different lengths of infusion and in normal volunteers as well as in migraine patients. The most obvious human model would therefore be to give GTN in the already validated dose of 0.5 mgkg 1 min 1 for 20 min (1,2) to migraine patients and test new drugs during the provoked migraine headache. However, such a model is highly impractical. First, it is difficult to recruit migraine patients for such experiments. Second, migraine attacks after GTN occur at highly variable time points ranging between 2 and 12 h after the Danish Headache Centre, Department of Neurology, University of Copenhagen, Glostrup Hospital, Glostrup, Denmark. Corresponding author: Dr Peer Tfelt-Hansen, Danish Headache Centre, Department of Neurology, University of Copenhagen, Glostrup Hospital, DK-2600, Glostrup, Denmark. ptha@glo.regionh.dk
2 Tvedskov et al. 929 infusion. Third, only 50 80% of migraine subjects developed an attack after GTN, which considerably weakens the statistical strengths of the experiments and necessitates fairly large numbers of subjects. Rather than using such a model, a drug would be tested in spontaneous migraine attacks. In this study we used normal subjects, because they are easy to recruit, because the immediate GTN headache has some migrainous features, and because nitric oxide (NO) is crucially involved in migraine mechanisms. We gave GTN in a protracted fashion in order to allow treatment during on-going headache rather than pretreatment. Thus, the treatment situation is similar to that in spontaneous headache attacks. Finally, we used a modest dose of GTN that could be expected to be easier to treat than headache after a higher standard dose. We used a general analgesic aspirin and a triptan, zolmitriptan, as validating drugs and tested the hypothesis that these drugs are effective in the described model. Subjects and methods Subjects Prior to study inclusion, it was ascertained that the subjects experienced headache after GTN 0.5 mg sublingually. Sixteen healthy medical student subjects without migraine and with no more then 2 days with tension-type headache per month were included. An additional nine subjects were screened but did not experience headache after a test dose of GTN 0.5 mg sublingually and were not included in the study. The subjects were recruited through advertising among medical students. Good general health was determined by medical history, physical examination, vital signs, electrocardiogram (ECG) and body mass index within the range kg/m 2. Women of child-bearing potential could participate provided they had a negative pregnancy test and used reliable contraceptive methods. Subjects with known allergy to the drugs used or with regular use of prescribed or over-the-counter medication except oral contraceptive pills were excluded. Study procedures The study had a double-blind, randomized, placebo-controlled, three-way crossover design. Subjects were all scheduled to have three study days separated by at least 7 days. On all three study days the subjects received an intravenous infusion of GTN mgkg 1 min 1 for 140 min in the cubital vein by a volume directed pump (IVAC P2000; Basingstoke, UK). GTN (SAD 5 mg/ml) was diluted with saline to a 50-ml 20-mg/ml solution. Supine position was assumed 30 min prior to GTN infusion and until at least 60 min after termination of the infusion. The start of GTN infusion was designated time zero. Subjects were randomized to receive either oral zolmitriptan 5 mg or effervescent acetylsalicylic acid 1000 mg or matched placebo 20 min into the GTN infusion. Randomization was performed by Astra Zeneca and the code was not known to the investigators until after the database was closed. With double dummy technique, zolmitriptan or matching placebo tablets were given with 100 ml of water and effervescent acetylsalicylic acid 1000 mg (2 500 mg Bamyl Õ ; Hässle, Mo lndal, Sweden) or matching placebo (Samarin, effervescent sodium bicarbonate) as a 200-ml oral solution, prepared by a person not otherwise involved in the study. Subjects were required to refrain from smoking while in the unit. Caffeine and alcohol intake was restricted in relation to the study days. Headache parameters Headache was scored on a numerical verbal rating scale from 0 to 10, where 0 represents no headache, 1 represents a very mild headache, including a feeling of pressing or pulsation (pre-pain), 5 represents a moderate headache and 10 represents the worst possible headache (2). Headache characteristics (unilateral/bilateral, quality and aggravation by physical activity) and accompanying symptoms (nausea/vomiting, phono- and photophobia) were recorded in order to compare with the International Headache Society (HIS) diagnostic criteria for migraine without aura (3). Headache parameters and accompanying symptoms were recorded in the clinic before study start and every 10 min until 60 min after termination of the infusion by a standardized questionnaire. Afterwards, the volunteers used a diary card at home to register headache until 12 h after the start of infusion. In case of severe headache, the subjects were offered rescue medication as paracetamol or non-steroidal anti-inflammatory drugs (NSAIDs). The ECG was monitored continuously and vital signs were obtained prior to start of study procedures and followed until 3 h after start of the GTN infusion. A follow-up clinical examination, including vital signs, ECG and evaluation of adverse events, was scheduled days after the last study day. This study was conducted from October 2000 to February Approvals were obtained from The Danish Medicines Agency and The Scientific Ethical Committee for the County of Copenhagen. Signed informed consent was obtained by each subject. The trial was conducted in accordance with the Declaration of Helsinki amended in Somerset West,
3 930 Cephalalgia 30(8) South Africa and conformed to rules for Good Clinical Practice. Statistics The primary efficacy parameters were peak headache (0 10) from 110 to 200 min (1.5 3 h after intake of study medication) and area under the curve (AUC) for headache from 80 to 200 (1 3 h after intake of study medication). Results for headache were analysed with non-parametric ANOVA, Friedman s test followed by Dunn s test. The design was powered to observe a 30% difference in headache scores with a type 1 error of 5% and risk of a type 2 error of 10%. For this 15 subjects were needed. Results Eight men and eight women participated. The mean age was 24 years (range years). GTN mgkg 1 min 1 for 140 min caused a mild headache that was usual constant, bilateral and with few accompanying symptoms. In each treatment group the headache was pulsating in four to seven subjects, was accompanied by nausea in 0 to two subjects, and by photophobia in two subjects. The headaches did not fulfil the IHS diagnostic criteria for migraine without aura (3). The one primary efficacy measure, peak of headache from 110 to 200 min, was 2.4 after zolmitriptan (range 0 5), 2.0 after aspirin (range 1 5) and 1.7 after placebo (range 0 9) (NS). The mean headache values for the three treatment arms are illustrated in Figure 1. For the other primary efficacy parameter, AUC for headache severity, the median value was 170 severity min (range ) after zolmitriptan, 130 severity min (range 0 375) after aspirin and 120 severity min (range 0 860) after placebo (NS). The mean baseline mean blood pressure was 84 mmhg and mean heart rate was 63 beats/min. After 20 min GTN infusion, before administration of test drugs, these parameters were largely unchanged with a mean blood pressure of 80 mmhg and a heart rate of 65 beats/min. After 140 min the mean blood pressure was 80 mmhg and the heart rate was 62 beats/min. Discussion The main result of the present study was that zolmitriptan and aspirin had no effect on continuing headache caused by a long-lasting infusion of a relatively low dose of GTN. Thus the experiment did not confirm our hypothesis that this design would be a useful surrogate marker of efficacy in spontaneous migraine attacks. This result is surprising and below we discuss the choice of model and of drugs as well as the possible reasons for their failure. Choice of model An experimental model must have significant advantages over the natural disease. Ease of recruitment of subjects, more standardized circumstances given better power, less requirement for toxicological studies and repeatability as well as being able to test in a hospital environment are examples of possible advantages of experimental human models. Regarding migraine, the GTN provocation model seems the most promising and it is certainly the best studied. It can be done in many varieties and the paradox is that the version most closely resembling spontaneous migraine attacks, the delayed migraine after GTN, is so difficult to use that, for the testing of new drugs, it is actually easier to test them in spontaneous attacks. For a model to be practically useful to the pharmaceutical industry, is should use normal subjects for ease of recruitment immediately on headache infusion in order to test the drug in a stable long-lasting headache. We designed such a model, but, as discussed above, it did not respond to standard treatments. Choice of validation drugs Aspirin was included in our study because it is the most used drug for migraine worldwide. Only 10 15% of migraineurs use a triptan in Denmark and the UK (4), while the rest probably use aspirin or another NSAID. Aspirin is a general analgesic with effect on almost all kinds of pain including episodic tension-type headache (5,6), and it is effective in human experimental pain models (7). Highly soluble aspirin 1000 mg is effective in migraine (8) but its mode of action in migraine is uncertain. Animal studies indicate that NSAIDs, including aspirin, may inhibit central trigeminal neurons in nucleus caudalis (9,10). This mechanism of action should work for all kinds of pain in the head, but aspirin was without any effect in the present vascular headache model. Zolmitriptan 5 mg, double the recommended dose of 2.5 mg (11), was expected to work in the GTN headache model in normal volunteers because sumatriptan given as 6 mg subcutaneously followed by GTN or placebo had effect in normal volunteers (12). Both headache and arterial dilation because of GTN were significantly decreased after sumatriptan from after placebo. Oral zolmitriptan has a significant effect in spontaneous migraine attacks detectable 30 min after administration and is probably maximal after 2 h (13). It also has vasoconstrictor effects in man. Thus, oral zolmitriptan 2.5 mg investigated in 16 migraine patients outside of
4 Tvedskov et al GTN infusion Mean headache Minutes Zolmitriptan+ placebo Placebo + placebo Aspirin + placebo Figure 1. Mean headache score during glyceryl trinitrate intravenous infusion (0.125 mgkg 1 min 1 ) for 140 min after oral placebo [placebo for aspirin (effervescent sodium carbonate) þ placebo for zolmitriptan], aspirin 1000 mg (þ placebo for zolmitriptan) and zolmitriptan 5 mg (þ placebo for aspirin). The vertical dotted line indicates the time point when the drugs were given. Note that there is absolutely no difference for aspirin and zolmitriptan vs. placebo. attack constricted both brachial, carotid and superficial temporal artery (STA) 1.5 h after intake (14). Sumatriptan was in the previous study (12) given as pretreatment, whereas zolmitriptan in the present study was given during a continued infusion of GTN. Thus, sumatriptan was already bound to the vascular receptor as demonstrated by constriction of the STA (12) before the GTN infusion was started, whereas zolmitriptan in the present study was administered during an ongoing GTN infusion. Possible mechanisms of action of NO, aspirin and zolmitriptan The GTN in the low dose used here caused only a mild headache in normal volunteers, and aspirin usually cures mild spontaneous headache. However, it has been suggested that aspirin works via inhibition of cyclooxygenase, thereby inhibiting the formation of prostanoids, some of which induce the formation of NO (15). If the mechanism of aspirin in mild to moderate spontaneous headache is to reduce prostanoid formation and the consequent reduction of NO formation, then this mechanism would be bypassed by exogenous NO delivered by GTN in the present study. How do we then explain the lack of effect of zolmitriptan? The most widely known mechanism of action of the triptans is cerebral vasoconstriction. Sumatriptan 6 mg given by subcutaneous (s.c.) injection constricts the middle cerebral, the middle meningeal artery and the STA (12,16). Given as a tablet, zolmitriptan had a smaller but significant constrictor effect on STA (14). It is possible that the vasoconstrictor effect of zolmitriptan in the present study was too small to influence GTN-induced headache, whereas the faster and greater effect of s.c. sumatriptan reduced nociceptive input. The other main mechanism of action of triptans is a binding to and stabilization of prejunctional nerve terminals to inhibit leakage of neurotransmitters into the perivascular space, or binding to the central terminal inhibiting impulse transduction at the first synapse (17,18). The neurotransmitters act on receptors in cellular membranes and subsequently on intracellular pathways. NO acts downstream of classical neurotransmitters by stimulating intracellular soluble guanylyl cyclase. It is therefore not surprising that stabilizing nerve terminals will have no effect on headache caused by NO. Implications for use of the GTN model in drug development With the present negative results at hand, how should a useful human model be designed? There are at least two possibilities. GTN may still be useful, but the active drug must then be given as pretreatment before GTN is administered. This was effective in our previous study (12), but probably because of a marked vasoconstrictor effect of s.c. sumatriptan. Thus, we are not optimistic about this model. The other possibility is to use other
5 932 Cephalalgia 30(8) provoking substances such as CGRP or other migraine-inducing substances. They may work higher in the cascade of migraine mechanisms and hence may be more responsive to migraine drugs. If that is so, it might be possible with such substances to use a design similar to that in the present study, i.e. giving the experimental treatment during continuing infusion of the migraine-inducing substance. The infusion would have to be continued for at least 2 h and preferably 3 h in order to give enough time for the drug to work. Conclusions A naturalistic human migraine model in non-migraine healthy volunteers cannot be developed with GTN, because: (i) GTN did not induce migraine headaches in our population; and (ii) neither aspirin nor zolmitriptan had any effect in such a model. Acknowledgements The study was supported by AstraZeneca and by the Lundbeck Foundation via the Lundbeck Foundation Centre for Neurovascular Signalling (LUCENS). References 1. Olesen J, Thomsen LL, Iversen H. Nitric oxide is a key molecule in migraine and other vascular headaches. TIPS 1994; 15: Iversen HK, Olesen J, Tfelt-Hansen P. Intravenous nitroglycerin as an experimental model of vascular headache. Basic characteristics. Pain 1989; 38: Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988; 8: Tfelt-Hansen P, Steiner TJ. Over-the-counter triptans for migraine: what are the implications? CNS Drugs 2007; 21: von Graffenried B, Hill RC. Headache as a model for testing mild analgesics. Res Clin Stud Headache 1978; 6: von Grafferied B, Hill RC, Nu esch E. Headache as a model for assessing mild analgesic drugs. J Clin Pharmacol 1980; 20: Barden J, Edwards JE, McQuay HJ, Moore AR. Pain and analgesic response after third molar extraction and other postsurgical pain. Pain 2004; 107: Lampl C, Voelker M, Diener HC. Efficacy and safety of 1,000 mg effervescent aspirin: individual patient data meta-analysis of three trials in migraine headache and migraine accompanying symptoms. J Neurol 2007; 254: Kaube H, Hoskin KL, Goadsby PJ. Intravenous acetylsalicylic acid inhibits central trigeminal neurons in the dorsal horn of the upper cervical spinal cord in the cat. Headache 1993; 33: Jakubowski M, Levy D, Kainz V, Zhang XC, Kosaras B, Burstein R. Sensitization of central trigeminovascular neurons: blockade by intravenous naproxen infusion. Neuroscience 2007; 148: Tfelt-Hansen P, De Vries P, Saxena PR. Triptans in migraine. A comparative review of pharmacology, pharmacokinetics and efficacy. Drugs 2000; 60: Iversen HK, Olesen J. Headache induced by nitric oxide donor (nitroglycerin) responds to sumatriptan. A human model for development of migraine drugs. Cephalalgia 1996; 16: Saxena PR, Tfelt-Hansen P. Triptans, 5HT1B/1D agonists in the acute treatment of migraine. In: Olesen J, Goadsby PJ, Ramadan NM, Tfelt-Hansen P, Welch KMA (eds) The headaches, 3rd ed. Philadelphia, PA: Lippincott Williams & Wilkins, 2006, p de Hoon JN, Willigers JM, Troost J, Struijker-Boudier HA, Van Bortel LM. Vascular effects of 5-HT1B/ 1D-receptor agonist in patients with migraine headaches. Clin Pharmacol Ther 2000; 68: Sakai M, Minami T, Hara I, Kitade H, Kamiyama Y, Okuda K, et al. Stimulation of nitric oxide release from rat spinal cord by prostaglandin E-2. Br J Pharmacol 1998; 123: Fullerton T, Komorowski-Swiatek D, Forrest A, Gengo FM. The pharmacodynamics of sumatriptan in nitroglycerin-induced headache. J Clin Pharmacol 1999; 39: Durham PL, Russo AF. New insight into molecular action of serotonergic antimigraine drugs. Pharmacol Ther 2002; 94: Levy D, Jakubowski M, Burstein R. Disruption of communication between peripheral and central trigeminovascular neurons by a 5HT 1B/1D receptor agonist: implications for migraine therapy with triptans. Proc Natl Acad Sci USA 2004; 101:
The effect of propranolol on glyceryltrinitrate-induced headache and arterial response
Blackwell Science, LtdOxford, UKCHACephalalgia0333-1024Blackwell Science, 2004241210761087Original ArticleEffect of propranolol on GTN-induced headache JF Tvedskov et al. The effect of propranolol on glyceryltrinitrate-induced
More informationACUTE TREATMENT FOR MIGRAINE. Cristina Tassorelli
The European Headache School 2012 ACUTE TREATMENT FOR MIGRAINE Cristina Tassorelli Headache Science Centre, IRCCS Neurological Institute C. Mondino Foundation - Pavia University Centre for Adaptive Disorders
More informationNitric oxide-induced headache in patients with chronic tension-type headache
Brain (2000), 123, 1830 1837 Nitric oxide-induced headache in patients with chronic tension-type headache M. Ashina, L. Bendtsen, R. Jensen and J. Olesen Department of Neurology, Glostrup Hospital, University
More informationCilostazol induced migraine does not respond to sumatriptan in a double blind trial
Falkenberg et al. The Journal of Headache and Pain (2018) 19:11 DOI 10.1186/s10194-018-0841-7 The Journal of Headache and Pain RESEARCH ARTICLE Open Access Cilostazol induced migraine does not respond
More informationIntroduction. Keywords: ergotamine, migraine, peripheral arteries, rizatriptan
The effect of rizatriptan, ergotamine, and their combination on human peripheral arteries: a double-blind, placebo-controlled, crossover study in normal subjects Peer Tfelt-Hansen, 1 Kaj Seidelin, 1 Michael
More informationADVANCES IN MIGRAINE MANAGEMENT
ADVANCES IN MIGRAINE MANAGEMENT Joanna Girard Katzman, M.D.MSPH Assistant Professor, Dept. of Neurology Project ECHO, Chronic Pain Program University of New Mexico Outline Migraine throughout the decades
More informationANTIMIGRAINE MEDICINES
1 07.00.00.00 - ANTIMIGRAINE MEDICINES 1. Summary statement For acute migraine therapy the following new medicine is proposed: Sumatriptan 50 mg. 2. 3. Global Campaign to Reduce the Burden of Headache
More informationA New Era of Migraine Management: The Challenging Landscape in Prevention
Provided by MediCom Worldwide, Inc. Supported by an educational grant from Teva Pharmaceuticals What is a Neuropeptide? Small chains of amino acids released by neural cells (neurons or glial cells) to
More informationMigraine: Developing Drugs for Acute Treatment Guidance for Industry
Migraine: Developing Drugs for Acute Treatment Guidance for Industry U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) February 2018
More informationChronic Migraine in Primary Care. December 11 th, 2017 Werner J. Becker University of Calgary
Chronic Migraine in Primary Care December 11 th, 2017 Werner J. Becker University of Calgary Disclosures Faculty: Werner J. Becker Relationships with commercial interests: Grants/Research Support: Clinical
More informationThe use of combination therapies in the acute management of migraine
REVIEW The use of combination therapies in the acute management of migraine Abouch Valenty Krymchantowski Headache Center of Rio, Rio de Janeiro, Brazil; Outpatient Headache Unit of the Instituto de Neurologia
More informationZomig. Zomig / Zomig-ZMT (zolmitriptan) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.22 Subject: Zomig Page: 1 of 5 Last Review Date: November 30, 2018 Zomig Description Zomig / Zomig-ZMT
More informationSumatriptan Tablets, Nasal Spray (Imitrex), Nasal Powder (Onzetra Xsail), sumatriptan and naproxen sodium (Treximet tablets)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 0 Subject: Sumatriptan Page: 1 of 6 Last Review Date: November 30, 2018 Sumatriptan Description Sumatriptan
More informationPrednisone vs. placebo in withdrawal therapy following medication overuse headache
doi:10.1111/j.1468-2982.2007.01488.x Prednisone vs. placebo in withdrawal therapy following medication overuse headache L Pageler 1,2, Z Katsarava 2, HC Diener 2 & V Limmroth 1,2 1 Department of Neurology,
More informationISPUB.COM. C Suthisisang, N Poolsup, N Suksomboon INTRODUCTION
ISPUB.COM The Internet Journal of Pain, Symptom Control and Palliative Care Volume 8 Number 2 Efficacy And Safety Of Sumatriptan Plus Naproxen Sodium In The Acute Treatment Of Migraine: Systematic Review
More informationAdvances in the Treatment of Migraine
Advances in the Treatment of Migraine C. Philip O Carroll, M.D. Director Neurobehavioral Medicine Hoag Neurosciences Institute Guyuron B Headache, 2015;55:1464-1473 I m sorry your head hurts, sweetie.is
More informationPrevention and Treatment of Migraines CAITLIN BARNES, PHARM.D. CANDIDATE AMBULATORY CARE JOE CAMMILLERI, PHARM.D. NATOHYA MALLORY, PHARM.D.
Prevention and Treatment of Migraines CAITLIN BARNES, PHARM.D. CANDIDATE AMBULATORY CARE JOE CAMMILLERI, PHARM.D. NATOHYA MALLORY, PHARM.D. Objectives Present patient case Review epidemiology/pathophysiology
More informationZolmitriptan is effective and well tolerated in Japanese patients with migraine: a dose response study
is effective and well tolerated in Japanese patients with migraine: a dose response study F Sakai 1, M Iwata 2, K Tashiro 3, Y Itoyama 4, S Tsuji 5, Y Fukuuchi 6, G Sobue 7, K Nakashima 8 & M Morimatsu
More informationmedications. This was an openlabel study consisting of patients with migraines who historically failed to respond to oral triptan
J Headache Pain (2007) 8:13 18 DOI 10.1007/s10194-007-0354-7 ORIGINAL Seymour Diamond Fred G. Freitag Alexander Feoktistov George Nissan Sumatriptan 6 mg subcutaneous as an effective migraine treatment
More informationGuidance for Industry Migraine: Developing Drugs for Acute Treatment
Guidance for Industry Migraine: Developing Drugs for Acute Treatment DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding this draft
More informationDespite the widespread use of triptans ... REPORTS... Almotriptan: A Review of Pharmacology, Clinical Efficacy, and Tolerability
... REPORTS... Almotriptan: A Review of Pharmacology, Clinical Efficacy, and Tolerability Randal L. Von Seggern, PharmD, BCPS Abstract Objective: This article summarizes preclinical and clinical data for
More informationZomig. Zomig / Zomig-ZMT (zolmitriptan) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.22 Subject: Zomig Page: 1 of 5 Last Review Date: March 16, 2018 Zomig Description Zomig / Zomig-ZMT
More informationSumatriptan Tablets, Nasal Spray (Imitrex), Nasal Powder (Onzetra Xsail), sumatriptan and naproxen sodium (Treximet tablets)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 05.70.10 Subject: Sumatriptan Page: 1 of 6 Last Review Date: March 16, 2018 Sumatriptan Description Sumatriptan
More informationDisclosures. Triptans for Kids 5/16/13
5/16/13 Disclosures Triptans for Kids Amy A. Gelfand, MD GelfandA@neuropeds.ucsf.edu Departments of Neurology and Pediatrics UCSF Child Neurology and Headache Center I receive grant funding from: NIH/NINDS
More informationONZETRA XSAIL (sumatriptan) nasal powder
ONZETRA XSAIL (sumatriptan) nasal powder Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy
More informationA new questionnaire for assessment of adverse events associated with triptans: methods of assessment influence the results. Preliminary results
J Headache Pain (2004) 5:S112 S116 DOI 10.1007/s10194-004-0123-4 Michele Feleppa Fred D. Sheftell Luciana Ciannella Amedeo D Alessio Giancarlo Apice Nino N. Capobianco Donato M.T. Saracino Walter Di Iorio
More informationAn Overview of MOH. ALAN M. Rapoport, M.D. Clinical Professor of Neurology The David Geffen School of Medicine at UCLA Los Angeles, California
An Overview of MOH IHS ASIAN HA MASTERS SCHOOL MARCH 24, 2013 ALAN M. Rapoport, M.D. Clinical Professor of Neurology The David Geffen School of Medicine at UCLA Los Angeles, California President-Elect
More informationFaculty Disclosures. Learning Objectives
WWW.AMERICANHEADACHESOCIETY.ORG Pathophysiology Content developed by: Andrew C. Charles, MD, FAHS, Peter J. Goadsby, MD, PhD, FAHS Donna Gutterman, PharmD Faculty Disclosures ANDREW C. CHARLES, MD, FAHS
More informationPosterior Cerebral Hypoperfusion in Migraine without Aura Marie Denuelle, MD Neurology Service, Rangueil Hospital Toulouse, France
Posterior Cerebral Hypoperfusion in Migraine without Aura Marie Denuelle, MD Neurology Service, Rangueil Hospital Toulouse, France Most of the cerebral blood flow (CBF) studies in migraine have introduced
More informationZolmitriptan nasal spray provides fast relief of migraine symptoms and is preferred by patients: a Swedish study of preference in clinical practice
J Headache Pain (2004) 5:237 242 DOI 10.1007/s10194-004-0132-3 ORIGINAL Carl G.H. Dahlöf Mattias Linde Erika Kerekes Zolmitriptan nasal spray provides fast relief of migraine symptoms and is preferred
More informationAtenolol in the prophylaxis of chronic migraine: a 3-month open-label study
Edvardsson SpringerPlus 2013, 2:479 a SpringerOpen Journal RESEARCH Open Access Atenolol in the prophylaxis of chronic migraine: a 3-month open-label study Bengt Edvardsson Abstract Background: Chronic
More informationEletriptan vs sumatriptan: A double-blind, placebo-controlled, multiple migraine attack study
Eletriptan vs sumatriptan: A double-blind, placebo-controlled, multiple migraine attack study G. Sandrini, M. Färkkilä, G. Burgess, et al. Neurology 2002;59;1210-1217 DOI 10.1212/WNL.59.8.1210 This information
More informationUpdate on Diagnosis and Management of Migraines
Update on Diagnosis and Management of Migraines Joel J. Heidelbaugh, MD, FAAFP, FACG Clinical Professor Departments of Family Medicine and Urology University of Michigan Learning Objectives To distinguish
More informationManaging Headache in Acute Medicine. Ben Lovell Consultant Physician in Acute Medicine University College London Hospital
Managing Headache in Acute Medicine Ben Lovell Consultant Physician in Acute Medicine University College London Hospital Some ED headache stats Arrive by ambulance 31% Median age 39 Worst ever headache
More information10/13/17. Christy M. Jackson, MD Director, Dalessio Headache Center Scripps Clinic, La Jolla Clinical Professor, Neurosciences UCSD
Christy M. Jackson, MD Director, Dalessio Headache Center Scripps Clinic, La Jolla Clinical Professor, Neurosciences UCSD } Depomed Consultant 2014 to present } Avanir Consultant 2014 to present } Amgen
More informationRizatriptan vs. ibuprofen in migraine: a randomised placebo-controlled trial
J Headache Pain (2007) 8:175 179 DOI 10.1007/s10194-007-0386-7 ORIGINAL Usha Kant Misra Jayantee Kalita Rama Kant Yadav Rizatriptan vs. ibuprofen in migraine: a randomised placebo-controlled trial Received:
More informationARxCH. Annual Review of Changes in Healthcare. Calcitonin Gene-Related Peptide Receptors and the Prevention of Migraines. Abstract
Calcitonin Gene-Related Peptide Receptors and the Prevention of Migraines Brian Schuler, PharmD Candidate 2018 1 1 University of Findlay College of Pharmacy Abstract Migraines are the third most prevalent
More informationComparison of dynamic (brush) and static (pressure) mechanical allodynia in migraine
Thomas Jefferson University Jefferson Digital Commons Department of Neurology Faculty Papers Department of Neurology July 2006 Comparison of dynamic (brush) and static (pressure) mechanical allodynia in
More informationMIGRAINE A MYSTERY HEADACHE
MIGRAINE A MYSTERY HEADACHE The migraine is a chronic neurological disease that is characterized by moderate to severe episodes of headache that is mostly associated with other central nervous system (CNS)
More informationCGRP, MONOCLONAL ANTIBODIES AND SMALL MOLECULES (-GEPANTS)
CGRP, MONOCLONAL ANTIBODIES AND SMALL MOLECULES (-GEPANTS) Hans-Christoph Diener Senior Professor of Clinical Neurosciences University Duisburg-Essen Germany CGRP, Monoclonal Antibodies and Small Molecules
More informationSUMAVEL DOSEPRO (sumatriptan succinate) solution for injection
SUMAVEL DOSEPRO (sumatriptan succinate) solution for injection Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit
More informationRavi Gupta Æ Tanzeel Ahmed Æ Basudeb Banerjee Æ Manjeet Bhatia
J Headache Pain (2009) 10:161 166 DOI 10.1007/s10194-009-0110-x ORIGINAL Plasma calcitonin gene-related peptide concentration is comparable to control group among migraineurs and tension type headache
More informationASSESSMENT OF HEADACHE IN MEN TAKING PHOSPHODIESTERASE-5 INHIBITOR (TADALAFIL) FOR ERECTILE DYSFUNCTION
Acta Medica Mediterranea, 2014, 30: 1007 ASSESSMENT OF HEADACHE IN MEN TAKING PHOSPHODIESTERASE-5 INHIBITOR (TADALAFIL) FOR ERECTILE DYSFUNCTION E. ESRA OKUYUCU*, OGUZ GUVEN**, EDIP UCAR***, TASKIN DUMAN*
More informationDisease Description and Statistics Current State: Medicare Denial of Coverage Expert Opinion Clinical Studies Gap in Medical Care Cost to US
Oxygen Therapy Disease Description and Statistics Current State: Medicare Denial of Coverage Expert Opinion Clinical Studies Gap in Medical Care Cost to US Taxpayers Recommendations Cluster headaches are
More informationClinical Learning Days November 10, 2017
Migraine Clinical Learning Days November 10, 2017 Alyssa Lettich. MD Neurosciences Institute/Neurosciences Clinical Program Medical Director Headache Disclosures: none Learning Objectives: At the conclusion
More informationPaediatric headaches. Dr Jaycen Cruickshank Director of Clinical Training Ballarat Health Services. Brevity, levity, repetition
Paediatric headaches Dr Jaycen Cruickshank Director of Clinical Training Ballarat Health Services Brevity, levity, repetition Paediatric)headache?)! Headache!in!children!is!not!that!common.!The!question!is!which!headaches!do!I!
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationHeadache Master School Japan-Osaka 2016 (HMSJ-Osaka2016) October 23, II. Management of Refractory Headaches
Headache Master School Japan-Osaka 2016 (HMSJ-Osaka2016) October 23, 2016 II. Management of Refractory Headaches Case presentation 1: A case of intractable daily-persistent headache Keio University School
More informationMIGRAINE A CAUSE OF INTENSE THROBBING; A MINI REVIEW
IJBPAS, January, 2016, 5(1): 87-92 ISSN: 2277 4998 MIGRAINE A CAUSE OF INTENSE THROBBING; A MINI REVIEW MUHAMMAD ZAMAN 1*, RABIA HASSAN 1, MUHAMMAD SHAFEEQ UR RAHMAN 2, MUHAMMAD HAFIZ ARSHAD 3, SYED ATIF
More informationIs the Migraid device an asset in the non-pharmacologic treatment of migraine?
Acta neurol. belg., 2007, 107, 40-46 Is the Migraid device an asset in the non-pharmacologic treatment of migraine? Herman PIETERSE 1,3, Joop A. M. KUSTER 2 and Luc M. VAN BORTEL 1 1 Heymans Institute
More informationPreventive Effect of Greater Occipital Nerve Block on Severity and Frequency of Migraine Headache
Proceeding S.Z.P.G.M.I. Vol: 31(2): pp. 75-79, 2017. Preventive effect of Greater Occipital Nerve Block on Severity and Frequency of Migraine Headache Dr. Syed Mehmood Ali, Dr. Mudassar Aslam, Dr. Dawood
More informationA Review of the Pharmacokinetics, Pharmacodynamics and Effi cacy of Zolmitriptan in the Acute Abortive Treatment of Migraine
A Review of the Pharmacokinetics, Pharmacodynamics and Effi cacy of Zolmitriptan in the Acute Abortive Treatment of Migraine A.A. Kalanuria 1 and B.L. Peterlin 1,2 REVIEW 1 Drexel University College of
More informationEarly treatment of a migraine attack while pain is still mild increases the efficacy of sumatriptan
Blackwell Science, LtdOxford, UKCHACephalalgia1468-2982Blackwell Science, 20042411925933Original ArticleEarly treatment of migraine with sumatriptanj Scholpp et al. Early treatment of a migraine attack
More informationHeadache A Practical Approach
Headache A Practical Approach Integrated Pain Symposium December 1, 2017 Alyssa Lettich. MD Neurosciences Institute/Neurosciences Clinical Program Medical Director Headache and Pain Development Teams Disclosures:
More informationSumatriptan Tablets, Nasal Spray (Imitrex), Nasal Powder (Onzetra Xsail), sumatriptan and naproxen sodium (Treximet tablets)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 05.70.10 Subject: Sumatriptan Page: 1 of 5 Last Review Date: December 2, 2016 Sumatriptan Description Sumatriptan
More informationMigraine and hormonal contraceptives
Migraine and hormonal contraceptives Department of Community Medicine, Systems Epidemiology University of Tromsø, November 2017 Nora Stensland Bugge Medical research student Presentation outline What is
More informationCalcitonin Gene Related Peptide Receptor Antagonist BIBN 4096 BS for the Acute Treatment of Migraine
The new england journal of medicine original article Calcitonin Gene Related Peptide Receptor Antagonist BIBN 4096 BS for the Acute Treatment of Migraine Jes Olesen, M.D., Hans-Christoph Diener, M.D.,
More informationTears of Pain SUNCT and SUNA A/PROFESSOR ARUN AGGARWAL RPAH PAIN MANAGEMENT CENTRE
Tears of Pain SUNCT and SUNA A/PROFESSOR ARUN AGGARWAL RPAH PAIN MANAGEMENT CENTRE IHS Classification 1989 (updated 2004) Primary Headaches 4 categories Migraine Tension-type Cluster and other trigeminal
More informationCalcitonin gene-related peptide in blood: is it increased in the external jugular vein during migraine and cluster headache?
J Headache Pain (2009) 10:137 143 DOI 10.1007/s10194-009-0112-8 REVIEW ARTICLE Calcitonin gene-related peptide in blood: is it increased in the external jugular vein during migraine and cluster headache?
More informationThe Clinical Profile of Sumatriptan: Cluster Headache Key Words
Paper Eur Neurol 1994;34(suppl 2):35-39 P.J. Peter J. Goadsby Department of Neurology, The Prince Henry Hospital, Little Bay, Sydney, NSW, Australia The Clinical Profile of Sumatriptan: Cluster Headache
More informationInvolvement of calcitonin gene-related peptide in migraine: regional cerebral blood flow and blood flow velocity in migraine patients
J Headache Pain (2008) 9:151 157 DOI 10.1007/s10194-008-0036-8 ORIGINAL Involvement of calcitonin gene-related peptide in migraine: regional cerebral blood flow and blood flow velocity in migraine patients
More informationCase Presentation. Case Presentation. Case Presentation. Truths about Headaches (2017) Most headaches were muscle-tension headaches
Agenda Case presentation Migraine Morphology Primary and Premonitory Phase Secondary Headache Aura Headache Primer on Pain Medication Overuse Headache Case Presentation RT is a 25 year old woman with daily
More informationRecognition and treatment of medication overuse headache
Recognition and treatment of medication overuse headache Marcus Lewis MA, MRCGP, DRCOG, DFSRH 20 Mean weekly headache index 15 10 5 Medication overuse headache is a common condition responsible for a high
More informationAdult with headache. Problem-specific video guides to diagnosing patients and helping them with management and prevention
Adult with headache Problem-specific video guides to diagnosing patients and helping them with management and prevention London Strategic Clinical Networks London Neuroscience Strategic Clinical Network
More informationClassification of headaches
Classification of headaches Jasna Zidverc Trajković Headache center Headache in adults: 1-year prevalence 13.4 Kryst 35.9 Miranda 28.7 Jaillard 87.3 O Brien 63.1 Wiehe 37.3 Lavados 59.7 Schwartz 76.0 Boardman
More informationACUTE MIGRAINE: OLD AND NEW DRUGS JOHN ROBROCK MD FORT WILLIAM FAMILY HEALTH TEAM
ACUTE MIGRAINE: OLD AND NEW DRUGS JOHN ROBROCK MD FORT WILLIAM FAMILY HEALTH TEAM Conflict of Interest Declaration: Nothing to Disclose Presenter: John Robrock, MD Title of Presentation: Acute Migraine:
More informationDisruption of communication between peripheral and central trigeminovascular neurons mediates the antimigraine action of 5HT 1B 1D receptor agonists
Disruption of communication between peripheral and central trigeminovascular neurons mediates the antimigraine action of 5HT 1B 1D receptor agonists Dan Levy*, Moshe Jakubowski*, and Rami Burstein* *Departments
More informationPatients preference for triptans and other medications as a tool for assessing the efficacy of acute treatments for migraine
J Headache Pain (2005) 6:112 120 DOI 10.1007/s10194-005-0164-3 REVIEW Andrew J. Dowson Stewart J. Tepper Carl Dahlöf Patients preference for triptans and other medications as a tool for assessing the efficacy
More informationDecentralised Procedure. Public Assessment Report. Zolmitriptan Renantos 2.5 mg Orodispersible film 5 mg Orodispersible film DE/H/2295/ /DC
Bundesinstitut für Arzneimittel und Medizinprodukte Decentralised Procedure Public Assessment Report Zolmitriptan Renantos 2.5 mg Orodispersible film 5 mg Orodispersible film DE/H/2295/001-002/DC Applicant:
More informationCan I send this headache patient home? Dr Nicola Giffin Consultant Neurologist Bath, Nov 2017
Can I send this headache patient home? Dr Nicola Giffin Consultant Neurologist Bath, Nov 2017 SAH v benign thunderclap headaches Other pathologies not apparent on CT Severe primary headaches: management
More informationReview of frovatriptan in the treatment of migraine
EXPERT OPINION Review of frovatriptan in the treatment of migraine Leslie Kelman Headache Center of Atlanta, Atlanta, GA, USA Abstract: Triptans are recommended for the acute treatment of moderate to severe
More informationDisclosures. Objectives 6/2/2017
Classification: Migraine and Trigeminal Autonomic Cephalalgias Lauren Doyle Strauss, DO, FAHS Assistant Professor, Child Neurology Assistant Director, Child Neurology Residency @StraussHeadache No disclosures
More informationAdult & Pediatric Patients. Stanford Health Care, Division Pain Medicine
Acute Treatment Strategies in Adult & Pediatric Patients Theresa Mallick Searle, MS, RN BC, ANP BC Disclosures Speakers Bureau: Allergan, Depomed Acute Treatment Strategies in Adult & Pediatric Patients
More informationMark W. Green, MD, FAAN
Mark W. Green, MD, FAAN Professor of Neurology, Anesthesiology, and Rehabilitation Medicine Director of Headache and Pain Medicine Icahn School of Medicine at Mt Sinai New York Pain-sensitive structures
More informationFamilial hemiplegic migraine
PHD THESIS DANISH MEDICAL BULLETIN Familial hemiplegic migraine An experimental genetic headache model Jakob Møller Hansen, MD This review has been accepted as a thesis together with four previously published
More informationMigraine headache is not associated with cerebral or meningeal vasodilatationça 3T magnetic resonance angiography study
doi:10.1093/brain/awn094 Brain (2008), 131, 2192^2200 Migraine headache is not associated with cerebral or meningeal vasodilatationça 3T magnetic resonance angiography study G. G. Schoonman, 1 J. van der
More informationSumatriptan Injection (Imitrex / Alsuma / Sumavel / Zembrace)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.11 Subject: Sumatriptan Injection Page: 1 of 6 Last Review Date: March 16, 2018 Sumatriptan Injection
More informationPreventive Effect of Greater Occipital Nerve Block on Severity and Frequency of Migraine Headache
Global Journal of Health Science; Vol. 6, No. 6; 2014 ISSN 1916-9736 E-ISSN 1916-9744 Published by Canadian Center of Science and Education Preventive Effect of Greater Occipital Nerve Block on Severity
More informationMigraine Management. Roger Cady, MD Headache Care Center Springfield, MO
Migraine Management Roger Cady, MD Headache Care Center Springfield, MO Disclosures Objectives The evolution of migraine From benign episodic (benign) headache to potentially a devastating chronic disease
More informationCurrent Migraine Treatment Therapy. Daniel Kassicieh, DO, FAAN
Current Migraine Treatment Therapy Daniel Kassicieh, DO, FAAN Migraine a Disease Process Migraines are a chronic disease process similar to many other chronic medical conditions Migraine has a low mortality
More informationTABLE 1. Current Diagnostic Criteria for Migraine Without Aura 2 A. At least 5 attacks fulfilling criteria B-D B. Headache attacks lasting 4-72 hours
ANSWERS CONCISE TO FREQUENTLY REVIEW ASKED QUESTIONS FOR CLINICIANS ABOUT MIGRAINE Answers to Frequently Asked Questions About Migraine IVAN GARZA, MD, AND JERRY W. SWANSON, MD Migraine is a common primary
More informationNitric oxide synthase inhibitors can antagonize neurogenic and calcitonin gene-related peptide induced dilation of dural meningeal vessels
British Journal of Pharmacology (2002) 137, 62 ± 68 ã 2002 Nature Publishing Group All rights reserved 0007 ± 1188/02 $25.00 www.nature.com/bjp Nitric oxide synthase inhibitors can antagonize neurogenic
More informationThe 45-year-old woman with monthly headaches. Anne MacGregor Barts and the London School of Medicine and Dentistry
The 45-year-old woman with monthly headaches Anne MacGregor Barts and the London School of Medicine and Dentistry Learning Objectives Use of diary cards for establishing patterns of attacks Importance
More informationMigraine. What are the symptoms of a migraine attack?
Migraine Migraine causes attacks of headaches, often with feeling sick or vomiting. Treatment options include: avoiding possible 'triggers', painkillers, antiinflammatory painkillers, anti-sickness medicines,
More informationPharmacology & Therapeutics
Pharmacology & Therapeutics 129 (2011) 332 351 Contents lists available at ScienceDirect Pharmacology & Therapeutics journal homepage: www.elsevier.com/locate/pharmthera Associate Editor: John Fozard Potential
More informationSeeking the best care for acute migraine
J Headache Pain (2002) 3:1 5 Springer-Verlag 2002 EDITORIAL Marcello Fanciullacci Seeking the best care for acute migraine M. Fanciullacci ( ) Headache Center, Department of Internal Medicine, University
More informationGreg Book. September 25, 2007 Olin Neuropsychiatry Research Center
Migraine Pathogenesis Greg Book September 25, 2007 Olin Neuropsychiatry Research Center Migraine Migraine i affects approximately 19.2% of females and 6.6% of males in the United States. (Patel, Bigal
More informationCEPMAGH. Optimal routes of administration of ergotamine tartrate in-cluster headache patients. A pharmacokinetic study* Introduction
Optimal routes of administration of ergotamine tartrate in-cluster headache patients. A pharmacokinetic study* K. Ekbom, A. E. Krabbe, G. Paalzow, L. Paalzow, P. Tfelt-Hansen and E. Waldenlind CEPMAGH
More informationMigraine Management. Dr Helen Brown Director of Neurology and Stroke The Princess Alexandra Hospital
Migraine Management Dr Helen Brown Director of Neurology and Stroke The Princess Alexandra Hospital Referral Criteria for Migraine Migraine Management Migraine Diagnosis Spot on Health Migraine pathway
More informationValue of postmarketing surveillance studies in achieving a complete picture of antimigraine agents: using almotriptan as an example
J Headache Pain (2006) 7:27 33 DOI 10.1007/s10194-006-0266-6 ORIGINAL Julio Pascual Hans-Christoph Diener Hélène Massiou Value of postmarketing surveillance studies in achieving a complete picture of antimigraine
More informationDavid W. Dodick M.D. Professor Director of Headache Medicine Department of Neurology Mayo Clinic Phoenix Arizona USA
Headache Masters School 2013 in Asia Sunday March 24, 2013 Procedural Medicine Workshop Onabotulinumtoxin A: Evidence, Injection Technique, and Mechanism of Action David W. Dodick M.D. Professor Director
More informationHow do we treat migraine? New SIGN Guidelines
How do we treat migraine? New SIGN Guidelines Managing your migraine Migraine Trust, Edinburgh 2018 Callum Duncan Consultant Neurologist Aberdeen Royal Infirmary Chair SIGN Guideline 155 Premonitory Mood
More informationHEADACHES THE RED FLAGS
HEADACHES THE RED FLAGS FAYYAZ AHMED CONSULTANT NEUROLOGIST HON. SENIOR LECTURER HULL YORK MEDICAL SCHOOL SECONDARY VS PRIMARY HEADACHES COMMON SECONDARY HEADACHES UNCOMMON BUT SERIOUS SECONDARY HEADACHES
More informationMIGRAINE UPDATE. Objectives & Disclosures. Learn techniques used to diagnose headaches. Become familiar with medications used for headache treatment.
MIGRAINE UPDATE Karen L. Bremer, MD November 16, 2018 Objectives & Disclosures Learn techniques used to diagnose headaches. Become familiar with medications used for headache treatment. Disclosure: I am
More informationMigraine Diagnosis and Treatment: Results From the American Migraine Study II
Migraine Diagnosis and Treatment: Results From the American Migraine Study II Richard B. Lipton, MD; Seymour Diamond, MD; Michael Reed, PhD; Merle L. Diamond, MD; Walter F. Stewart, MPH, PhD Objective.
More informationExploring daytime sleepiness during migraine
Exploring daytime sleepiness during migraine J.H.M. TULEN 1, D.L. STRONKS 1,2, L. PEPPLINKHUIZEN 1, J. PASSCHIER 2 DEPARTMENTS OF PSYCHIATRY 1 AND MEDICAL PSYCHOLOGY & PSYCHOTHERAPY 2, UNIVERSITY HOSPITAL
More informationDo you suffer from Headaches? - November/Dec 2011
Do you suffer from Headaches? - November/Dec 2011 Inside this month's issue Headaches Acute single headaches Recurring Headaches: Migraine What causes Migraine? Treatments for migraine & prevention Headaches
More informationA synopsis of: Diagnosis and Management of Headaches in Adults: A national clinical guideline. Scottish intercollegiate Guidelines Network SIGN
A synopsis of: Diagnosis and Management of Headaches in Adults: A national clinical guideline Scottish intercollegiate Guidelines Network SIGN November 2008. PETER FRAMPTON MSc MCOptom BAppSc (Optom)(AUS)
More informationNee Kong CHEW, Chong Tin TAN, Heng Thay CHONG, Yau Hoong CHAN, Kuoh Ren CHONG, Hee Hong LAM, Yan Beng NGE, Chek Tung NGO.
Neurol J Southeast Asia 2001; 6 : 13 17 Ramadan headache Nee Kong CHEW, Chong Tin TAN, Heng Thay CHONG, Yau Hoong CHAN, Kuoh Ren CHONG, Hee Hong LAM, Yan Beng NGE, Chek Tung NGO. Department of Medicine,
More informationManagement of headache
Management of headache TJ Steiner Imperial College London Based on European principles of management of common headache disorders TJ Steiner, K Paemeleire, R Jensen, D Valade, L Savi, MJA Lainez, H-C Diener,
More information